top of page

SPOKE Cloud Demos

PPMS Drug Development

Five years ago researchers used Mate’s Compound-Protein binding algorithm and SPOKE degree weighted path count to screen all the compounds in ChEMBL for a primary progressive MS treatment. This resulted in a list of over 500 candidate drugs. These compounds were then rigorously tested on their ability to: increase OPC differentiation to oligodendrocyte, increase remyelination, and preserve neuronal viability and morphology. Today, when you run the same workflow in SPOKE Cloud to rank compounds, the most promising treatment from the wet lab experiments is ranked #4.

Weight Loss Drug Development

With Mate’s Compound-Protein binding endpoint and SPOKE degree weighted path count, researchers can quickly screen and prioritize millions of compounds. In this demo, we examine the set of compounds protected by Pfizer’s Glp-1 receptor agonist patent. We also demonstrate how easy it is to leverage built-in graph algorithms on graph projections.

bottom of page